Shots:
- Shilpa Biologicals has entered into an exclusive MENA licensing & commercialization agreement with SPIMACO Bio for a portfolio of PD-1 inhibitor biosimilars used in cancer immunotherapy
- Shilpa Biologicals will lead exclusive development & manufacturing, with phased technology transfer to enable local biosimilar production in Saudi Arabia, while SPIMACO Bio will handle regulatory execution, market access & commercialization across the MENA region
- The partnership aims to expand access to affordable immunotherapy, strengthen Saudi Arabia’s biomanufacturing capabilities, support Vision 2030 goals, & create long-term value for Shilpa Biologicals
Ref: Shilpa Biologicals | Image: SPIMACO Bio & SPIMACO Bio | Reference
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
